With an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The com...

Precision oncology startup 4baseCare has raised Rs 128 crore. This funding will expand its genomics labs globally and scale its AI platform...

As global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...

The study, which followed patients for over five years, found that those ⁠who received ⁠the regimen were nine times more likely to have lit...

Novartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, e...

Space stem cell research is rapidly changing cancer treatment and regenerative medicine worldwide. Scientists aboard the International Spac...

Shamir Chandran, a cancer specialist doctor of Indian origin, has been banned from practicing medicine in Britain. He was convicted of cont...

Novartis India country president and managing director Amitabh Dube said India is gradually moving beyond its traditional role as a clinica...

Roche Pharma India introduces a new injectable immunotherapy for lung cancer. This treatment takes only seven minutes, a significant reduct...

Roche Pharma has introduced Tecentriq, India's first under-the-skin immunotherapy for lung cancer. This new injection takes about seven min...

The funds will be used for expanding operations, opening new centres, and diversifying the range of services offered, said the Mumbai-based...

Aurigene Oncology has announced promising phase-1 results for its novel CAR-T cell therapy, Ribrecabtagene autoleucel, in patients with mul...

This was stated by the Drugs Controller General of India in a letter to to HCG Bangalore Institute of Oncology Speciality Centre. The permi...

Doctors said the new treatment can improve response rates (increase the rate of tumour shrinkage) and delay cancer progression.

The oncology market in India is growing at 20 per cent annually and is expected to touch Rs 3,831 crore by 2017.

Veeda Oncology on Tuesday said it has completed the acquisition of Paris-based Biologie et Industrie bolstering its presence in the segment.

Dabur Pharma is working on 17 new chemical entities and will launch 12 generic products in the US by the next year.